Ultrasonication of insulin-loaded microgel particles produced by internal gelation: impact on particle's size and insulin bioactivity.
Alginate-dextran sulfate (ADS) microgel has been used to protect insulin from gastrointestinal attack and as a carrier to promote insulin permeation through intestinal epithelium. The throughput of ADS submicron particles generation by emulsification/internal gelation is limited by its wide size distribution. The aim of this work was to study the recovery protocol influence on ADS particles through the determination of its impact on particles' size distribution and bioactivity. ADS particles showed a wide and multimodal distribution, characterized by a high aggregation phenomenon. In an attempt to reverse particles' tendency to aggregate and to homogenize particle size ADS populations were submitted to ultrasonication, while particle size distribution, physical and chemical stability, and the bioactivity of entrapped insulin were investigated. After ultrasonication a narrower particle population shifted to the nanoscale, with higher physical stability and significant insulin bioactivity was obtained. Emulsification internal/gelation followed by ultrasonication constituted a valid strategy to obtain ADS particles at the submicron range, with high stability and without significantly compromising insulin bioactivity, so offering promises, under previously well established conditions, to evaluate impact of ADS particle's size on biopharmaceutical and pharmacokinetics phases.
Centro de Estudos Farmacêuticos, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
Ana C
AC
Santos
Joana
J
Cunha
F
F
Veiga
A
A
Cordeiro-da-Silva
Antonio J
AJ
Ribeiro
D000464:Alginates / Q000737:chemistry*; D000818:Animals; D016264:Dextran Sulfate / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry* / Q000494:pharmacology; D004339:Drug Compounding; D004355:Drug Stability; D005427:Flocculation; D005782:Gels; D015870:Gene Expression / Q000187:drug effects; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D007328:Insulin / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008823:Micelles; D041681:NIH 3T3 Cells; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D013010:Sonication
D000464:Alginates; D004337:Drug Carriers; D005782:Gels; D006603:Hexuronic Acids; D007328:Insulin; D008823:Micelles; D020723:Glucuronic Acid; D016264:Dextran Sulfate; D051057:Proto-Oncogene Proteins c-akt
ADS; ANOVA; CD; Cryo-SEM; DLS; DMEM; Dulbecco's modified eagle medium; ELS; Emulsion; FBS; Hydrogels; In vitro models; LD; LOD; NPs; PI; Particle size; Physical stability; Ultrasound; alginate/dextran sulfate; circular dichroism; cryo-scanning electron microscopy; dynamic light scattering; electrophoretic light scattering; fetal bovine serum; laser diffractometry; limit of detection; nanoparticles; one way analysis of variance; polydispersity index; w/o; water/oil